Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00717 | Boc-Val-Dil-Dap-Doe | 135383-62-9 |
| Boc-Val-Dil-Dap-Doe is a compound used to synthesize Dolastatin 10. Dolastatin 10 is a potent cytotoxin and involves inhibition of tubulin polymerization, tubulin-dependent guanosine triphosphate hydrolysis, and nucleotide exchange. | Inquiry | |
| BADC-00718 | Boc-Val-Dil-Dap-Nrp | |
| Boc-Val-Dil-Dap-Nrp is an effective ADC cytotoxin payload with optimized linker design, facilitating targeted release of cytotoxic agents in antibody-drug conjugates for improved therapeutic index. | Inquiry | |
| BADC-00720 | Tubulysin IM-2 | |
| Tubulysin IM-2 can be used in the synthesis of Tubulysin M. Tubulysin M is a Tubulysin D is a cytotoxic activity tubulysin which inhibits tubulin polymerization and leads to cell cycle arrest and apoptosis. Tubulysin M is used as the cytotoxin in antibody-drug conjugates | Inquiry | |
| BADC-00721 | Tubulysin IM-3 | |
| Tubulysin IM-3 can be used in the synthesis of Tubulysin anologs. Tubulysin anologs is a class of microtubule-disrupting agents and can be used as cytotoxins in antibody-drug-conjugation (ADC). | Inquiry | |
| BADC-00771 | Thailanstatin B | |
| Thailanstatin B is an ADC payload that inhibits pre-mRNA splicing, disrupting cancer cell gene expression. This ADC cytotoxin improves antibody-drug conjugate specificity and potency, suitable for novel targeted cancer therapies. | Inquiry | |
| BADC-00772 | Thailanstatin C | |
| Thailanstatin C serves as a spliceosome inhibitor ADC payload, inducing apoptosis by interfering with RNA processing in tumor cells. It enhances the therapeutic index of antibody-drug conjugates in oncology applications. | Inquiry | |
| BADC-00773 | Thailanstatin D | |
| Thailanstatin D is a potent ADC cytotoxin payload targeting spliceosome function to disrupt cancer cell survival. Incorporated in antibody-drug conjugates, it supports innovative precision oncology drug development. | Inquiry | |
| BADC-00774 | Fr901463 | |
| a potent cell cycle inhibitor. Fr901463 exhibited potent antitumor activities against tumor cell lines via binding to the spliceosome and modulating pre-mRNA splicing. | Inquiry | |
| BADC-00777 | Meayamycin | |
| Meayamycin is a highly selective ADC payload inhibiting spliceosome activity, leading to apoptosis in tumor cells. It boosts the efficacy of antibody-drug conjugates in targeted cancer therapy. | Inquiry | |
| BADC-00778 | Pladienolide B | 445493-23-2 |
| a potent pre-mRNA splicing inhibitor. Pladienolide B has shown strong inhibitory effect against activity and growth of various cell lines via targeting SF3b. | Inquiry | |
| BADC-00779 | Pladienolide D | |
| Pladienolide D is an ADC cytotoxin payload that disrupts spliceosome assembly, impairing cancer cell RNA processing. Its use in antibody-drug conjugates enhances selective cytotoxicity and therapeutic outcomes. | Inquiry | |
| BADC-00781 | Spliceostatin B | |
| Spliceostatin B acts as a spliceosome inhibitor ADC payload, inducing tumor cell death by blocking RNA splicing. This ADC cytotoxin enhances antibody-drug conjugate specificity for targeted cancer treatment. | Inquiry | |
| BADC-00782 | Spliceostatin C | |
| Spliceostatin C is a potent ADC payload targeting spliceosome function, leading to cancer cell apoptosis. Incorporated in antibody-drug conjugates, it improves targeted chemotherapy effectiveness. | Inquiry | |
| BADC-00783 | Sudemycin C | |
| Sudemycin C is an ADC cytotoxin payload that inhibits spliceosome activity, disrupting gene expression in tumor cells and triggering apoptosis. It supports precision oncology through antibody-drug conjugates. | Inquiry | |
| BADC-00785 | Sudemycin E | 1197054-49-1 |
| Sudemycin E serves as a spliceosome-targeting ADC payload, promoting selective cancer cell death by interfering with RNA processing. Its integration into antibody-drug conjugates advances targeted therapy approaches. | Inquiry | |
| BADC-00786 | Sudemycin E0 | |
| Sudemycin E0 is an innovative ADC cytotoxin payload that disrupts pre-mRNA splicing in tumor cells, enhancing antibody-drug conjugate specificity and efficacy in cancer treatment. | Inquiry | |
| BADC-00787 | Sudemycin F1 | |
| Sudemycin F1 functions as a potent ADC payload inhibiting spliceosome components, inducing apoptosis in malignant cells. It improves therapeutic outcomes in antibody-drug conjugates for oncology applications. | Inquiry | |
| BADC-00792 | Illudin M | 1146-04-9 |
| Illudin M is a natural product-derived ADC cytotoxin payload inducing DNA damage and apoptosis. It enhances antibody-drug conjugate performance by selectively targeting tumor cells and facilitating payload delivery in oncology treatments. | Inquiry | |
| BADC-00793 | PDM3 | |
| 20-O-Deme-thylansamitocin P-3 (PDM3),an ansamacrolide and maytansine analogue, has a greater antitumor activities against P388 and L 1210 than AP3. | Inquiry | |
| BADC-00794 | Esperamicin | |
| Esperamicinis an antitumor antibiotics, which combines the structural features of the anthracyclines and the enediynes. Esperamicinis are extremely toxic DNA splicing compounds and exhibits highly potent antitumor activity. | Inquiry |
